• Facebook - Grey Circle
  • YouTube - Grey Circle

© 2018 Dr.Brie.com. Proudly created by BluRiver Creative Co.

Policies & Terms of Use

Target b2™ with Hereditum Lc40 is a targeted probiotic designed to extend the benefits of breastfeeding and support overall infant immune health. This strain of Lactobacillus Fermentum (CECT5716) is clinically demonstrated to support breast health and resolve discomfort associated with mammary dysbiosis.

 

As many as one third of lactating women experience significant discomfort resulting in premature cessation of breastfeeding. Studies have shown that lactic acid bacteria isolated from human milk may prevent and resolve lactation-associated mammary dysbiosis. Colonizing Lactobacilli were isolated from the breast milk of healthy mothers. The strain was specifically selected for its safety of origin, antimicrobial, and immunomodulatory properties.

 

It is recommended to start supplementation with one capsule of Target b2™ in the third trimester of pregnancy and continue while nursing to help prevent mammary dysbiosis. During an active case of mammary dysbiosis three capsules at 9 billion CFU is recommended.

Target B2

$55.00Price
  • Introduction

    Exclusive breastfeeding is recommended by the World Health Organization for infants up to at least 6 months of age.1 Breast milk provides all the nutrients and components necessary for proper infant development and growth. Moreover, breastfeeding also appears to have important effects on the infant microbiome that can be determinative of later health. Unfortunately, during the first weeks of breastfeeding, women often experience a range of discomforts and breast health issues that can interfere with lactation and nursing.

    Breast milk is one of the primary contributors to the development of gut microbiota of the infant. Enteric-breast circulation occurs and is higher in late pregnancy and lactation. This may explain why orally administered probiotic supplements can directly influence health of breast microbiota.2 Although the study of probiotics in human milk is a relatively recent field of research, the existence of a human milk microbiome has been described for more than a decade.

    Current research is focused on bacterial composition of the breast milk microbiome, as well as on how the maternal environment and mode of delivery influence it. Under healthy conditions, breast milk has been shown to contain Lactobacilli, Streptococci, Staphylococci, Enterococcus spp, and Bifidobacteria, as the predominant bacterial groups.3 Although they may alter bacterial load, conventional drug treatment options fall short when it comes to relieving breastfeeding discomforts, and have well-documented negative impact on the maternal and infant microbiota.4

    Research has shown that Lactobacilli isolated from breast milk demonstrate significant immunomodulatory properties.†5 Recent studies further demonstrate that breast comfort, infant immune health, and the balance of bacteria in the breast and gut microbiota can be favorably influenced by supplementation with probiotics. Target b2 is a novel probiotic formula containing Lactobacillus fermentum CECT5716 (Hereditum Lc40), a unique strain clinically shown to improve breast comfort in breastfeeding women and immune health in infants.†

     

    Product features

    • Clinically shown to support infant immune health†

    • Clinically demonstrated to provide a safe and effective approach to

      preventing, reducing, and resolving lactation discomforts and dysbiosis†

     

    Target b2 clinical research

    L. fermentum CECT5716 (Hereditum Lc40) has been shown to provide a safe and effective approach to maximizing breastfeeding comfort and duration while supporting infant immune health. Many clinical trials have validated the efficacy of L. fermentum in human health. Two clinical trials to date have specifically demonstrated its effects on breast health.

     

    In an open-label, 3-arm study comparing two strains of Lactobacilli and conventional treatment in 352 women with lactation-related discomfort and mammary dysbiosis,6 L. fermentum CECT5716 (Hereditum Lc40) and another, commercially unavailable, Lactobacillus strain were administered at 9 billion CFU per day for 21 days. A third (control) group received conventional treatment. On day 0, the mean bacterial counts in milk samples of the three groups were similar, and Lactobacilli could not be detected. On day 21, mean bacterial counts in the probiotic groups were significantly improved compared with the control group. Women taking probiotics showed more improvements in comfort and had less recurrence compared to the conventional method. The authors concluded that L. fermentum CECT5716 represented an efficient alternative for supporting breast comfort and healthy microbiota during breastfeeding.†

     

    †Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.Information provided is in no way a diagnosis or prescription from Dr. Brie, this is not medical advice and it is recommended you consult your family's physician prior to use.

    klaire.com I 888 488 2488